Navigation Links
Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
Date:4/29/2009

ise sufficient funds for development or working capital; that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; and that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients. and. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including its Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; its annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by Forms 10-K/A filed with the SEC on December 23, 2008 and April 20, 2009; and its Form 10-Q filed with the SEC on April 13, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons -acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. Raptor expressly disclaims any intent or obligation t
'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Pressure BioSciences, ... leader in the development and sale of broadly ... to the worldwide life sciences industry, today announced ... of Molecular Systems Biology, ETH Zurich, presented data ... and classification of prostate cancer tissue biopsy samples ...
(Date:6/29/2015)... , June 29, 2015  The automotive ... features to cars on the basis of consumer ... industry is now on the verge of integrating ... While automotive HWW non-critical features such as reconfigurable ... present in 30 to 40 percent of all ...
(Date:6/29/2015)... and EWING, N.J. , June 29, ... ) today announced that The Leukemia & Lymphoma Society ... the final payment linked to the Phase 3 study ... for the treatment of patients with high-risk (secondary) acute myeloid ... of $400,000 originally attached to the final overall survival ...
Breaking Medicine Technology:Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 3Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 4Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 2The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 3The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 4The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 5The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 6
... Medical, Inc. (OTC Bulletin Board: HASC ), ... patients in Alabama, Florida, and Mississippi, today announced it ... 8,000+ products available for immediate delivery. The ... affordable for patients throughout the United States to order ...
... are reporting problems receiving required home medical equipment and ... implementation of Medicare,s controversial "competitive" bidding program in Miami ... The program will affect many of the more than ... Miami and Orlando who are enrolled in Medicare. ...
Cached Medicine Technology:HASCO Medical Expands Online Offering 2Seniors in Florida Report Problems Obtaining Needed Home Medical Equipment and Services Under Controversial Medicare Bidding System 2Seniors in Florida Report Problems Obtaining Needed Home Medical Equipment and Services Under Controversial Medicare Bidding System 3Seniors in Florida Report Problems Obtaining Needed Home Medical Equipment and Services Under Controversial Medicare Bidding System 4
(Date:6/29/2015)... YORK (PRWEB) , ... June 29, 2015 , ... ... (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device is ... and is an alternative to continuous positive airway pressure (CPAP), the current standard ...
(Date:6/29/2015)... ... ... People across the country give their coworkers and families gifts all the time. From holiday ... how often do coworkers donate “life” to the husband of a coworker? For one VA ... (Wright-Thompson) told me her husband was on a donor list,” Glenshaw resident Kathi Dahl said. ...
(Date:6/29/2015)... ... ... USA Today reported on June 18th the overdose death rate has ... rest of the nation’s growing overdose death rates in 26 other states the U.S. ... stop the increasing overdose trend from continuing: , , Encourage and ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has released ... to French consumers. , The specialized eye health formulation contains a variety of ... radicals. In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, ...
(Date:6/29/2015)... ... June 29, 2015 , ... DISC, ... behavior, is a popular focus for corporate training seminars. As many as seventy ... improve training, foster teamwork, and increase productivity. , With the demand for ...
Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Overdose Death Rates Decreased in Florida as of 2015 2Health News:Overdose Death Rates Decreased in Florida as of 2015 3Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:As Demand for DISC Trainers Rises, PeopleKeys Offers Support with “THE DISC FACTOR—Train the Trainer” Webinar 2
... more clinical preventive services, dedicate funding source to public ... 11 Partnership for Prevention today unveiled health ... and health promotion efforts to tackle the chronic diseases ... , Under these proposals, federally ...
... Inc. (Nasdaq: PTIE ) has received a Complete Response ... New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of ... the NDA is not approved in its present form. ... non-clinical data will be required to support the approval of REMOXY. ...
... touted as the "cure" for health care, but a new ... that implementation of technology and related devices is not a ... safety of patient care. , , ... to understanding when a technology may (or may not) be ...
... Dental Management,Services, Inc. (Nasdaq: BDMS ), operators ... The Company,s board of directors,has declared a quarterly ... stock.,The dividend is payable January 9, 2009, to shareholders ... Birner Dental Management Services, Inc. acquires, develops, ...
... agonists may cause asthma problems and death, agency officials ... of four asthma medications will be weighed by a U.S. ... hearings end Thursday. , The controversy over these drugs has ... recently calling for banning the use of these drugs for ...
... PRA International, a leading,Clinical Research Organization, announces ... Mexico. With years of long-standing South American ... The region,s existing base of clinical,sites with expertise ... to PRA,s therapeutic focus. The expansion is ...
Cached Medicine News:Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:PRA International Expands Operations in Mexico 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: